A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2032-11-30

Summary

This study will be conducted to compare Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.

• Phase: PHASE3

Details

• Lead Sponsor: Incyte Corporation
• Treatments: axatilimab; Calcineurin Inhibitors; Cyclosporine; Everolimus; ibrutinib; Imatinib Mesylate; Mycophenolic Acid; Pentostatin; Photopheresis; Proteasome Inhibitors; Rituximab; Sirolimus; Tacrolimus